Filing Flows › Myriad Genetics (MYGN) › Stock forecast & fair value
Myriad Genetics (MYGN) stock forecast and price target
Myriad Genetics (MYGN) trades at $5.92. 8 analysts' median price target is $4.60 (-22%), from $2.50 to $8.00.
Myriad Genetics' latest quarter
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MYGN stock?
The median of 8 analysts' 12-month targets is $4.60, -22% from $5.92; the range is $2.50 to $8.00. The average rating is hold.
Does Myriad Genetics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is MYGN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.